Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
Go back to Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias| (NASDAQ: SNDX) | Delayed: 19.32 +0.32 (1.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.00 | 52 Week High | $18.03 | |||
| Open | $19.21 | 52 Week Low | $8.97 | |||
| Day High | $19.59 | P/E | N/A | |||
| Day Low | $18.94 | EPS | $0.00 | |||
| Volume | 1,836,656 | |||||
